268 related articles for article (PubMed ID: 33159829)
1. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Shiota M; Terada N; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Mizowaki T; Kamoto T; Kojima T; Kitamura H; Sugimoto M; Nishiyama H; Eto M;
Cancer Sci; 2021 Apr; 112(4):1524-1533. PubMed ID: 33159829
[TBL] [Abstract][Full Text] [Related]
2. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
Shiota M; Terada N; Kitamura H; Kojima T; Saito T; Yokomizo A; Kohei N; Goto T; Kawamura S; Hashimoto Y; Takahashi A; Kimura T; Tabata KI; Tomida R; Hashimoto K; Sakurai T; Shimazui T; Sakamoto S; Kamiyama M; Tanaka N; Mitsuzuka K; Kato T; Narita S; Yasumoto H; Teraoka S; Kato M; Osawa T; Nagumo Y; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Inoue T; Sugimoto M; Mizowaki T; Kamoto T; Nishiyama H; Eto M;
Cancer Sci; 2021 Sep; 112(9):3616-3626. PubMed ID: 34145921
[TBL] [Abstract][Full Text] [Related]
3. Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With
Kobayashi T; Namitome R; Hirata YU; Shiota M; Imada K; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2019 Jun; 39(6):3191-3195. PubMed ID: 31177166
[TBL] [Abstract][Full Text] [Related]
4. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan.
Narita S; Hatakeyama S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Koizumi A; Mitsuzuka K; Tochigi T; Tsuchiya N; Ohyama C; Arai Y; Nomura K; Habuchi T
Int J Clin Oncol; 2020 May; 25(5):912-920. PubMed ID: 31919691
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
9. Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8.
Morozumi K; Mitsuzuka K; Narita S; Takahashi M; Kawamura S; Tochigi T; Arai Y; Hoshi S; Shimoda J; Ishidoya S; Okamoto T; Hatakeyama S; Sakurai T; Tsuchiya N; Ohyama C; Habuchi T; Ito A
Int J Urol; 2022 Apr; 29(4):324-331. PubMed ID: 35042278
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
Nagumo Y; Onozawa M; Kojima T; Terada N; Shiota M; Mitsuzuka K; Yasumoto H; Matsumoto H; Enokida H; Sugiyama T; Kuroiwa K; Saito T; Yokomizo A; Kohei N; Tabata KI; Takahashi A; Sugimoto M; Kitamura H; Kamoto T; Nishiyama H;
Int J Urol; 2022 May; 29(5):398-405. PubMed ID: 35080069
[TBL] [Abstract][Full Text] [Related]
11. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
J Cancer Res Clin Oncol; 2015 Mar; 141(3):495-503. PubMed ID: 25227457
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study.
Yamada Y; Sakamoto S; Sato K; Saito S; Kanesaka M; Rii J; Kurokawa K; Tachiwaki D; Fukui Y; Shibata H; Goto Y; Sazuka T; Imamura Y; Nakatsu H; Ichikawa T
Prostate; 2023 Dec; 83(16):1610-1618. PubMed ID: 37690087
[TBL] [Abstract][Full Text] [Related]
13. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
Ebbinge M; Berglund A; Varenhorst E; Hedlund PO; Sandblom G;
BJU Int; 2018 Oct; 122(4):583-591. PubMed ID: 29611275
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
Turner PG; Jain S; Cole A; Grey A; Mitchell D; Prise KM; Hounsell AR; McGarry CK; Biggart S; O'Sullivan JM
Clin Cancer Res; 2021 Aug; 27(16):4549-4556. PubMed ID: 34187853
[TBL] [Abstract][Full Text] [Related]
16. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.
Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
Anticancer Res; 2022 Feb; 42(2):1107-1114. PubMed ID: 35093913
[TBL] [Abstract][Full Text] [Related]
18. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Clarke NW; Ali A; Ingleby FC; Hoyle A; Amos CL; Attard G; Brawley CD; Calvert J; Chowdhury S; Cook A; Cross W; Dearnaley DP; Douis H; Gilbert D; Gillessen S; Jones RJ; Langley RE; MacNair A; Malik Z; Mason MD; Matheson D; Millman R; Parker CC; Ritchie AWS; Rush H; Russell JM; Brown J; Beesley S; Birtle A; Capaldi L; Gale J; Gibbs S; Lydon A; Nikapota A; Omlin A; O'Sullivan JM; Parikh O; Protheroe A; Rudman S; Srihari NN; Simms M; Tanguay JS; Tolan S; Wagstaff J; Wallace J; Wylie J; Zarkar A; Sydes MR; Parmar MKB; James ND
Ann Oncol; 2019 Dec; 30(12):1992-2003. PubMed ID: 31560068
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a novel risk model in newly diagnosed
Zhang Y; Wang J; Ding L; Zheng Y; Wu C; Wang K; Xia W; Ge P
PeerJ; 2023; 11():e14615. PubMed ID: 36650836
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
